Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801
Clinical and Translational Oncology · 2025
DOI: 10.1007/s12094-025-04098-3 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical and Translational Oncology, 2025. Verfasst von Enrique Espinosa und 32 weiteren Autor:innen. Beteiligte Einrichtung: Universidad Autónoma de Madrid, School of Medicine-Hospital Universitario La Paz, CIBERONC, Madrid, Spain. enrique.espinosa@uam.es. Hauptthemen laut MEDLINE: Melanoma, Immunotherapy, Skin Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad Autónoma de Madrid.
Abstract (Originalsprache)
Purpose
Anti-PD-1-based immunotherapy and targeted therapies (TT) are the current standard of care for patients with advanced melanoma. However, some patients die in less than a year from diagnosis and others become long-survivors. An accurate description of systemic treatments and patients’ characteristics of long-term survivors are needed to guide treatment decisions in clinical practice.
Methods
GEM-1801 is a multi-cohort prospective study from the Spanish Multidisciplinary Melanoma Group that includes patients with resectable stage III or unresectable stage III/IV melanoma. Patients surviving at least 5 years and patients surviving less than 1 year since diagnosis were selected. Baseline characteristics and first and second-line systemic treatments are described and compared between groups.
Results
From Aug 2018 to Dec 2023, 60 patients with long-term survival and 216 patients with short-term survival were included. Long-term survivors received immunotherapy (65%), including anti-PD-1 in 86% and combination of an anti-PD-1 and anti-CTLA-4 in 14%; and TT (35%). The Objective Response Rate (ORR) was 76% for anti-PD-1, 80% for combination immunotherapy and 83% for TT. Short-term survivors received immunotherapy (58%), including anti-PD-1 (70%), anti-CTLA-4 (1%), and anti-PD-1 plus anti-CTLA-4 (29%); TT (36%); and chemotherapy (2%). ORR was 7% for anti-PD-1, 0% for anti-CTLA-4, 14% for combination immunotherapy, 53% for TT and 0% for chemotherapy.
Conclusions
Response to first or second-line systemic treatment may be a surrogate for long-term survival patients with advanced melanoma. Clinical trial identification Clinicaltrials.gov: NCT03605771
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Universidad Autónoma de Madrid, School of Medicine-Hospital Universitario La Paz, CIBERONC, Madrid, Spain. enrique.espinosa@uam.es.
- Medical Oncology Department, Hospital Regional Universitario (HRU), Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Málaga, Spain.
- Medical Oncology Department, Hospital Universitari Vall d'Hebron y Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
- Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain.
- Medical Oncology Department, Instituto Catalán de Oncología, ICO-Badalona, H. Germans Trias i Pujol, Badalona, Spain.
- Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Förderung
- Universidad Autónoma de Madrid
Zitieren
APA
Espinosa, E., Berciano-Guerrero, M. Á., Muñoz-Couselo, E., Puértolas, T., Manzano, J. L., Soria, A., de Miguel, P. A., Crespo, G., Sanz, L. G., Cerezuela-Fuentes, P., de la Rosa, C. A., Majem, M., Castaño, A. G., Berrocal, A., Arroyo, F. R. G., de la Borbolla, M. R., Bellido, L., Martínez, J. M., Fernández, L. A., …, & Márquez-Rodas, I. (2025). Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-025-04098-3
Vancouver
Espinosa E, Berciano-Guerrero MÁ, Muñoz-Couselo E, Puértolas T, Manzano JL, Soria A, et al. Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801. Clinical and Translational Oncology. 2025. doi:10.1007/s12094-025-04098-3
BibTeX
@article{Espinosa2025,
author = {Espinosa, Enrique and Berciano-Guerrero, Miguel-Ángel and Muñoz-Couselo, Eva and Puértolas, Teresa and Manzano, José Luis and Soria, Ainara and de Miguel, Pablo Ayala and Crespo, Guillermo and Sanz, Lourdes Gutiérrez and Cerezuela-Fuentes, Pablo and de la Rosa, Carlos Aguado and Majem, Margarita and Castaño, Almudena García and Berrocal, Alfonso and Arroyo, Francisco Ramon García and de la Borbolla, María Rodríguez and Bellido, Lorena and Martínez, Javier Medina and Fernández, Luis Antonio and Carnicero, Alfonso Martin and Castro, Rafael López and Rodríguez, Aida Bujosa and Lecumberri, Mª José and Guzmán, José Carlos Villa and Balea, Begoña Campos and Rodríguez, Joaquín Fra and Bautista, Javier Valdivia and Pérez, Victor Navarro and Mujika, Karmele and Subias, Mónica Corral and Hernández, Berta and Algarra, Salvador Martín and Márquez-Rodas, Iván},
title = {Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801},
journal = {Clinical and Translational Oncology},
year = {2025},
doi = {10.1007/s12094-025-04098-3}
}
EUVIMED